Susquehanna International Group, LLP X4 Pharmaceuticals, Inc Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$0.54 - $0.86 $9,828 - $15,652	-18,200 Reduced 39.06%	28,400 $19,000
Q2 2024 Aug 15, 2024	SELL	$0.58 - $1.47 $91,234 - $231,231	-157,300 Reduced 77.15%	46,600 $27,000
Q1 2024 May 07, 2024	BUY	$0.72 - $1.46 $90,792 - $184,106	126,100 Added 162.08%	203,900 $283,000
Q4 2023 Feb 14, 2024	BUY	$0.61 - $0.99 $36,478 - $59,202	59,800 Added 332.22%	77,800 $65,000
Q3 2023 Nov 14, 2023	SELL	$1.03 - $2.02 $174,688 - $342,592	-169,600 Reduced 90.41%	18,000 $19,000
Q2 2023 Aug 11, 2023	BUY	$0.82 - $2.49 $122,016 - $370,512	148,800 Added 383.51%	187,600 $363,000
Q1 2023 May 16, 2023	SELL	$0.8 - $1.22 $2,960 - $4,514	-3,700 Reduced 8.71%	38,800 $33,000
Q4 2022 Feb 14, 2023	BUY	$0.69 - $2.21 $20,769 - $66,521	30,100 Added 242.74%	42,500 $42,000
Q3 2022 Nov 14, 2022	BUY	$0.89 - $1.71 $11,036 - $21,204	12,400 New	12,400 $21,000

104

100M

213K

50.6K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $24M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.